Drug companies' evidence to justify advertising

Simple item page
dc.contributor.authorWade, V.A.
dc.contributor.authorMansfield, P.R.
dc.contributor.authorMcDonald, P.J.
dc.date.issued1989
dc.descriptionOriginally published as Volume 2, Issue 8674
dc.description.abstractTen international pharmaceutical companies were asked by letter to supply their best evidence in support of marketing claims for seventeen products. Fifteen replies were received. Seven replies cited a total of 67 references: 31 contained relevant original data and only 13 were controlled trials, all of which had serious methodological flaws. There were four reports of changes in advertising claims and one company ceased marketing nikethamide in the third world. Standards of evidence used to justify advertising claims are inadequate.
dc.description.statementofresponsibilityV.A. Wade, P.R. Mansfield, P.J. Mcdonald
dc.identifier.citationThe Lancet, 1989; 334(8674):1261-1264
dc.identifier.doi10.1016/S0140-6736(89)91862-X
dc.identifier.issn0140-6736
dc.identifier.issn1474-547X
dc.identifier.orcidMansfield, P.R. [0009-0006-6697-8687]
dc.identifier.urihttp://hdl.handle.net/2440/91331
dc.language.isoen
dc.publisherElsevier
dc.rights© 1989 Published by Elsevier Ltd.
dc.source.urihttps://doi.org/10.1016/s0140-6736(89)91862-x
dc.subjectProduct Surveillance, Postmarketing
dc.subjectFraud
dc.subjectDeveloping Countries
dc.subjectAdvertising
dc.subjectDrug Industry
dc.subjectHealth Promotion
dc.subjectEvaluation Studies as Topic
dc.titleDrug companies' evidence to justify advertising
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Public Health publications